AbbVie to Acquire Apogee Therapeutics for $135.11 per Share; Apogee Surges Over 55% Pre-Market

According to reports, AbbVie announced on June 22 that it will acquire Apogee Therapeutics for $135.11 per share in an all-cash transaction. Apogee shares surged over 55% in pre-market trading following the announcement.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments